Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
November 21, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer...
Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022 09:00 ET
|
Sensei Biotherapeutics
- SNS-101, a highly pH-selective antibody to VISTA, demonstrated anti-tumor effects and promising pharmacokinetic properties in preclinical studies - - Characterization of endogenous expression...
Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
November 08, 2022 07:30 ET
|
Sensei Biotherapeutics
- Recent SNS-101 preclinical data demonstrate a favorable pharmacokinetic profile, evidence of advanced anti-tumor effects and a superior cytokine release profile - - New preclinical data on multiple...
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”
November 07, 2022 07:30 ET
|
Sensei Biotherapeutics
Featuring Dr. Robert Schreiber, globally recognized expert on the immune system’s role in anti-cancer immunity Pre-registration available for live event, to be held November 21, 2022, at 2:15 p.m....
Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
November 02, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer,...
Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022 08:05 ET
|
Sensei Biotherapeutics
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer,...
Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
September 30, 2022 16:05 ET
|
Sensei Biotherapeutics
- SNS-101 demonstrated a favorable pharmacokinetic profile, enhanced anti-tumor effects in combination with anti-PD-1 antibodies and a significantly improved cytokine release profile as compared to a...
Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
September 21, 2022 16:05 ET
|
Sensei Biotherapeutics
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for...
Sensei Biotherapeutics Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, a pH-selective VISTA-blocking Antibody
August 31, 2022 07:30 ET
|
Sensei Biotherapeutics
BOSTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for...